Mariam Alexander, MD, PhD
Dr. Mariam Alexander is a thoracic medical oncologist. Her patient care focuses on those diagnosed with lung cancer and solid tumors like malignant pleural mesothelioma, and she specializes in the use of targeted therapies to provide better outcomes.[1]
As part of the multidisciplinary lung and thoracic oncology team at Hollings Cancer Center and the Medical University of South Carolina, Dr. Alexander works with radiation oncologists, surgeons, pulmonologists, and advanced practice professionals in support of patients. She is enthusiastic about the range of innovative treatments available for patient care, including immunotherapy. She says that tailoring the patient’s treatment to genetic analysis of their disease provides a more personalized approach with better options.[1]
Education and Career
Dr. Alexander earned her medical degree at Saba University School of Medicine, then completed her internship and residency in Internal Medicine at SUNY Upstate Medical Center. Her fellowship training in Hematology and Oncology was completed at the Montefiore Medical Center in New York City, and she also earned her Ph.D. in molecular biology and genetics at the University of Toronto, Canada.[1]
Research
Dr. Alexander’s research is focused on solid tumor biology, with a special focus on lung cancer and targeted therapies. Her current studies include:[2]
- A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer
- A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation
- A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants With Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab
- A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
- A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
